These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32240559)

  • 1. Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica.
    Ma C; Wang S; Wang G; Wu Y; Yang T; Shen W; Zhuang Y; Zhang L; Liu X; Yang L; Feng Y; Yu Y; Liu Z; Wang D
    J Clin Apher; 2020 Jun; 35(3):206-216. PubMed ID: 32240559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource-Limited Settings: Outcomes in a Multiethnic Single-Center Population.
    Ong ZM; Schee JP; Viswanathan S
    Ther Apher Dial; 2020 Jun; 24(3):312-323. PubMed ID: 31654607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee.
    Ipe TS; Raval JS; Fernando LP; Gokhale A; Jacquot C; Johnson AD; Kim HC; Monis GF; Mo YD; Morgan SM; Pagano MB; Pham HP; Sanford K; Schmidt AE; Schwartz J; Waldman A; Webb J; Winters JL; Wu Y; Yamada C; Wong ECC
    J Clin Apher; 2020 Jan; 35(1):25-32. PubMed ID: 31705563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica.
    Pereira WLCJ; Reiche EMV; Kallaur AP; Oliveira SR; Simão ANC; Lozovoy MAB; Schiavão LJV; Rodrigues PRDVP; Alfieri DF; Flauzino T; Kaimen-Maciel DR
    Acta Neuropsychiatr; 2017 Jun; 29(3):170-178. PubMed ID: 27692000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromyelitis optica spectrum disorder and systemic lupus erythematosus.
    Thabah MM; D S; Pranov R; Moulitej MMV; Ramesh A; Kadhiravan T
    Lupus; 2019 Dec; 28(14):1722-1726. PubMed ID: 31722604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.
    Kinoshita M; Nakatsuji Y; Kimura T; Moriya M; Takata K; Okuno T; Kumanogoh A; Kajiyama K; Yoshikawa H; Sakoda S
    Biochem Biophys Res Commun; 2009 Sep; 386(4):623-7. PubMed ID: 19545538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.
    Freitas E; Guimarães J
    Rheumatol Int; 2015 Feb; 35(2):243-53. PubMed ID: 24952418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
    Jarius S; Wildemann B
    Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.
    Soltys J; Liu Y; Ritchie A; Wemlinger S; Schaller K; Schumann H; Owens GP; Bennett JL
    J Clin Invest; 2019 Apr; 129(5):2000-2013. PubMed ID: 30958797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder.
    Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH
    J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
    Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
    Duan T; Tradtrantip L; Phuan PW; Bennett JL; Verkman AS
    Neuropharmacology; 2020 Jan; 162():107827. PubMed ID: 31654702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and classification of neuromyelitis optica (Devic's syndrome).
    Drori T; Chapman J
    Autoimmun Rev; 2014; 13(4-5):531-3. PubMed ID: 24424197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.
    Nicchia GP; Mastrototaro M; Rossi A; Pisani F; Tortorella C; Ruggieri M; Lia A; Trojano M; Frigeri A; Svelto M
    Glia; 2009 Oct; 57(13):1363-73. PubMed ID: 19229993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review.
    Pereira WL; Reiche EM; Kallaur AP; Kaimen-Maciel DR
    J Neurol Sci; 2015 Aug; 355(1-2):7-17. PubMed ID: 26050520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.
    Miyazaki-Komine K; Takai Y; Huang P; Kusano-Arai O; Iwanari H; Misu T; Koda K; Mitomo K; Sakihama T; Toyama Y; Fujihara K; Hamakubo T; Yasui M; Abe Y
    Br J Pharmacol; 2016 Jan; 173(1):103-14. PubMed ID: 26398585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica.
    Cayrol R; Saikali P; Vincent T
    Ann N Y Acad Sci; 2009 Sep; 1173():478-86. PubMed ID: 19758189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.